At Lupin, behind every product manufactured or a formulation created lies the power of science. Our intellectual capacity resides in subject matter expertise, passion for innovation and in-depth research. In everything we do, here at Lupin, science is reflected through our Research and Development unit and our continuous focus on Digital Transformation.
Innovation at Lupin is driven by a single motivation; to deliver advanced, accessible and safe healthcare solutions to reduce the burden of diseases globally.
Our globally spread R&D centers and team of scientists bring deep domain knowledge across complex generics, specialty formulations, active pharmaceutical ingredients (API) and novel therapies.
With 41 product filings and 52 approvals in FY25, Lupin is gaining momentum in complex generics and active pharmaceutical ingredients. Our Intellectual Property Management Group plays a vital role in safeguarding innovations across APIs, biologics, and novel chemical entities.
In FY25, we secured 87 patents out of which 6 were for formulations and 81 for new chemical entities.
Our New Chemical Entity (NCE) team, with a strategic focus on oncology, immunology, and metabolic disorders, is advancing novel therapeutics from early-stage research through clinical development. These efforts underscore our commitment to delivering breakthrough medicines that transform lives.
At Lupin, our digital ambition is anchored in our purpose, to catalyze treatments that transform hope into healing.
From Labs to Lives - We aspire to build an intelligent, resilient, and trusted enterprise where digital capabilities strengthen how we operate, innovate, and scale.
We are realizing this ambition through a Core–Common–Distinct business capability model, guided by clear enterprise architecture principles.
business capabilities provide a secure, reliable backbone for the enterprise.
business capabilities are designed for reuse and consistency across the organization.
business capabilities enable our businesses (manufacturing, quality, R&D, supply chain, and commercial), to innovate and differentiate with agility, while staying aligned to enterprise standards.
Our enterprise architecture principles ensure that we remain experience-led, data-first, cloud-enabled, AI-powered, and quality-by-design. These principles help us make disciplined technology choices, reduce complexity, and scale innovation responsibly.
A unified GenAI platform, strong data foundations, and platform-led design allow intelligence to be embedded seamlessly into everyday decisions and operations.
Ultimately, our digital ambition is about people, purpose, and performance. Through proactive communication, team collaboration and by building AI fluency, we create shared momentum and confidence in change.
This is how Lupin continues to strengthen its digital foundation, running with purpose, growing with resilience, and innovating without limits.
We do this to deliver better healthcare outcomes for patients worldwide.
